Physician profile
David B Samimi
NPI 1306044102
$2,247.22
in general payments reported to CMS, 2019-2025
14 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $142 · 2021: $167 · 2022: $236 · 2023: $226 · 2024: $944 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,325.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $797.83 | 2022-2024 | |
| Allergan, INC. | $264.08 | 2019-2021 | |
| Amgen INC. | $167.46 | 2024-2025 | Tepezza |
| Axogen | $138.70 | 2025 | |
| Integra Lifesciences Corporation | $135.47 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Novartis Pharmaceuticals Corporation | $133.82 | 2019 | |
| Galderma Laboratories, L.P. | $125.00 | 2020 | |
| Bausch & Lomb Americas INC. | $124.99 | 2024 | Xiidra, Miebo |
| Tarsus Pharmaceuticals, INC. | $119.89 | 2024 | Xdemvy |
| Stryker Corporation | $84.03 | 2019 | |
| Merz North America, INC. | $77.45 | 2023 | Xeomin |
| Horizon Therapeutics Plc | $39.73 | 2019-2021 | |
| Janssen Biotech, INC. | $21.53 | 2019 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Samimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.